Contrasting Bavarian Nordic (BVNRY) and Its Competitors

Bavarian Nordic (OTCMKTS: BVNRY) is one of 89 publicly-traded companies in the “Biological products, except diagnostic” industry, but how does it weigh in compared to its peers? We will compare Bavarian Nordic to related businesses based on the strength of its valuation, profitability, dividends, institutional ownership, analyst recommendations, risk and earnings.

Valuation and Earnings

This table compares Bavarian Nordic and its peers revenue, earnings per share (EPS) and valuation.

Gross Revenue Net Income Price/Earnings Ratio
Bavarian Nordic $208.06 million $27.54 million 33.00
Bavarian Nordic Competitors $1.05 billion $96.36 million -0.70

Bavarian Nordic’s peers have higher revenue and earnings than Bavarian Nordic. Bavarian Nordic is trading at a higher price-to-earnings ratio than its peers, indicating that it is currently more expensive than other companies in its industry.

Institutional and Insider Ownership

47.4% of shares of all “Biological products, except diagnostic” companies are owned by institutional investors. 16.5% of shares of all “Biological products, except diagnostic” companies are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Analyst Ratings

This is a summary of current ratings and target prices for Bavarian Nordic and its peers, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Bavarian Nordic 0 1 0 0 2.00
Bavarian Nordic Competitors 454 1688 4517 148 2.64

As a group, “Biological products, except diagnostic” companies have a potential upside of 23.10%. Given Bavarian Nordic’s peers stronger consensus rating and higher probable upside, analysts clearly believe Bavarian Nordic has less favorable growth aspects than its peers.

Volatility and Risk

Bavarian Nordic has a beta of 0.41, meaning that its stock price is 59% less volatile than the S&P 500. Comparatively, Bavarian Nordic’s peers have a beta of 1.59, meaning that their average stock price is 59% more volatile than the S&P 500.


This table compares Bavarian Nordic and its peers’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Bavarian Nordic 13.47% 8.04% 6.25%
Bavarian Nordic Competitors -5,580.57% -62.17% -25.06%


Bavarian Nordic peers beat Bavarian Nordic on 9 of the 13 factors compared.

About Bavarian Nordic

Bavarian Nordic A/S, a biotechnology company, develops, manufactures, and commercializes a portfolio of novel vaccines for the prevention and treatment of life-threatening infectious diseases and cancer. The company markets non-replicating smallpox vaccine under the IMVAMUN and IMVANE names. It is also developing MVA-BN Filo that is in Phase III trial for the treatment of Ebola and Marburg; MVA-BN RSV, which is in Phase II clinical development stage for the prevention of respiratory syncytial virus; and MVA-BN HPV that is in preclinical development stage to treat human papillomavirus. In addition, the company is developing PROSTVAC, which is in Phase III clinical development for the treatment of asymptomatic or minimally symptomatic metastatic castration-resistant prostate cancer; CV301 that is in Phase II clinical trial for the treatment multiple cancers; and MVA-BN Brachyury that has completed Phase I clinical trial for the treatment of metastatic cancer. The company has collaboration agreements with National Cancer Institute; Bristol-Myers Squibb; Janssen Pharmaceuticals, Inc.; and Biomedical Advanced Research and Development Authority. It also has a license and collaboration agreement with Janssen Pharmaceuticals, Inc. to leverage its MVA-BN technology with Janssen's AdVac and DNA-based vaccine technologies for the development and commercialization of new vaccine regimens against hepatitis B virus (HBV) and human immunodeficiency virus (HIV-1); and collaboration agreement with US Department of Defense for the development of a prophylactic vaccine against the equine encephalitis virus. The company operates in the United States, Holland, Canada, and internationally. Bavarian Nordic A/S was founded in 1994 and is headquartered in Kvistgaard, Denmark.

Receive News & Ratings for Bavarian Nordic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bavarian Nordic and related companies with's FREE daily email newsletter.

Leave a Reply